The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(rac)-(1R,2S)-2-(3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one ID: ALA4546145
PubChem CID: 58486228
Max Phase: Preclinical
Molecular Formula: C27H26N6O
Molecular Weight: 450.55
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: CN1CCN(c2ccc(-c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cn2)CC1
Standard InChI: InChI=1S/C27H26N6O/c1-32-10-12-33(13-11-32)24-9-7-18(16-28-24)25-19-8-6-17(14-23(19)30-31-25)21-15-27(21)20-4-2-3-5-22(20)29-26(27)34/h2-9,14,16,21H,10-13,15H2,1H3,(H,29,34)(H,30,31)/t21-,27-/m0/s1
Standard InChI Key: IKVNNBYIDXRNMG-IDISGSTGSA-N
Molfile:
RDKit 2D
34 40 0 0 0 0 0 0 0 0999 V2000
19.3326 -19.8307 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.5369 -19.6182 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.7507 -20.4136 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.7843 -19.9496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.2407 -19.3309 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.6568 -18.6198 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.4672 -18.8015 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.0277 -18.1912 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.7791 -17.3991 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.9647 -17.2207 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.4078 -17.8323 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.6042 -20.7544 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
20.0614 -19.4446 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.7571 -19.8852 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.8123 -18.2365 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.0868 -18.6243 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.5161 -18.6747 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.4880 -19.5019 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.2662 -19.7844 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.7752 -19.1314 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.3115 -18.4458 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.5778 -17.6682 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.3880 -17.5083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.6533 -16.7281 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
23.1092 -16.1071 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.2966 -16.2715 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.0351 -17.0515 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.3739 -15.3296 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
24.1840 -15.1693 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.4487 -14.3919 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.9070 -13.7695 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
23.0970 -13.9298 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.8286 -14.7125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.1741 -12.9891 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
1 3 1 0
2 4 1 1
2 7 1 0
6 5 1 0
5 4 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
10 11 2 0
11 6 1 0
4 12 2 0
1 13 1 6
13 14 2 0
14 18 1 0
17 15 1 0
15 16 2 0
16 13 1 0
17 18 2 0
18 19 1 0
19 20 1 0
20 21 2 0
21 17 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 26 1 0
26 27 2 0
27 22 1 0
21 22 1 0
28 29 1 0
28 33 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 33 1 0
25 28 1 0
31 34 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 450.55Molecular Weight (Monoisotopic): 450.2168AlogP: 3.75#Rotatable Bonds: 3Polar Surface Area: 77.15Molecular Species: NEUTRALHBA: 5HBD: 2#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 13.09CX Basic pKa: 7.45CX LogP: 3.82CX LogD: 3.49Aromatic Rings: 4Heavy Atoms: 34QED Weighted: 0.50Np Likeness Score: -0.64
References 1. Li SW, Liu Y, Sampson PB, Patel NK, Forrest BT, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Hodgson R, Beletskaya I, Mao G, Mason JM, Wei X, Luo X, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.. (2016) Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy., 26 (19): [PMID:27592744 ] [10.1016/j.bmcl.2016.08.063 ]